Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial

NCT05492409 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT05492409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05492409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial
Lead sponsor
AO GENERIUM
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2022
Completion date
April 3, 2024
Enrollment
160 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura